Poly drug use, chemsex drug use, and associations with sexual risk behaviour in HIV-negative men who have sex with men attending sexual health clinics

Sexualized drug use ('chemsex') and high-risk sexual behaviours in HIV-positive men who have sex with men.

OBJECTIVES The incidence of sexually transmitted infections (STIs) and HIV infection remains high in gay, bisexual, and other men who have sex with men (MSM) in the UK, and sexualized drug use ("chemsex") and injecting drug use ("slamsex") may play a part in this. We aimed to characterize HIV-positive MSM engaging in chemsex/slamsex and to assess the associations with self-reported STI diagnose...

Drug--using men who have sex with men: sexual behaviours and sexual identities

Men who have sex with men (MSM) and use drugs are at high risk for HIV. This study assessed drug and sex-related risk behaviours and sexual identities for MSM drug injectors and crack smokers. One hundred and forty four MSM drug injectors and crack smokers from five USA cities were interviewed. One-third of the men were current injectors, twice as many reported lifetime injection. Most (56%) re...

Impact of Mobile Phone-Based Interventions on Methamphetamine Use and High-risk Sexual Behaviors in Men Who Have Sex with Men (MSM): A Systematic Review

Understanding the HIV Risk and Sexual Health Needs of Men Who Have Sex with Men

I N S I D E Understanding the HIV risk and sexual health needs of men who have sex with men ...............2 Reducing HIV-related stigma ...............................3 Improving the lives of children orphaned or made vulnerable by HIV and AIDS...................... 4 Promoting gender equity to fight HIV ............... 5 Increasing access to antiretroviral therapy for HIV-infected adults and ...

HIV, HCV, and drug use in men who have sex with men.

1 Rummel MJ, Niederle N, Maschmeyer G, et al. Bendamustine plus rituximab versus CHOP plus rituximab as fi rst-line treatment for patients with indolent and mantle-cell lymphomas: an open-label, multicentre, randomised, phase 3 non-inferiority trial. Lancet 2013; 381: 1203–10. 2 Federico M, Luminari S, Dondi A, et al. R-CVP versus R-CHOP versus R-FM for the initial treatment of patients with ad...